S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:IFRX

InflaRx (IFRX) Stock Forecast, Price & News

$4.15
-0.06 (-1.43%)
(As of 06/5/2023 ET)
Compare
Today's Range
$4.11
$4.26
50-Day Range
$1.78
$6.10
52-Week Range
$0.78
$7.25
Volume
183,196 shs
Average Volume
345,001 shs
Market Capitalization
$185.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

InflaRx MarketRank™ Forecast

Analyst Rating
Buy
3.20 Rating Score
Upside/​Downside
237.3% Upside
$14.00 Price Target
Short Interest
Healthy
1.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.26) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

534th out of 985 stocks

Pharmaceutical Preparations Industry

261st out of 483 stocks


IFRX stock logo

About InflaRx (NASDAQ:IFRX) Stock

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Stock News Headlines

SVB Securities Reaffirms Their Buy Rating on InflaRx (IFRX)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Raymond James Remains a Buy on InflaRx (IFRX)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
LifeSci Capital Reaffirms Their Buy Rating on InflaRx (IFRX)
InflaRx N.V.'s (NASDAQ:IFRX) Profit Outlook
InflaRx (NASDAQ:IFRX) PT Lowered to $9.00 at HC Wainwright
InflaRx Announces Public Offering of Ordinary Shares
InflaRx (NASDAQ:IFRX) Stock Rating Upgraded by Guggenheim
Why Shares of InflaRx Are Soaring Wednesday
See More Headlines

IFRX Price History

IFRX Company Calendar

Last Earnings
5/11/2023
Today
6/06/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IFRX
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+237.3%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Net Income
$-31,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.08 per share

Miscellaneous

Free Float
37,417,000
Market Cap
$185.51 million
Optionable
Not Optionable
Beta
0.97

Key Executives

  • Niels Christoph Riedemann
    Chief Executive Officer & Executive Director
  • Thomas Taapken
    Chief Financial Officer
  • Renfeng Guo
    Executive Director & Chief Scientific Officer
  • Maria Habel
    VP, Head-Pre-Clinical Research & Development
  • Bruce P. Burnett
    Vice President & Head-Medical Affairs













IFRX Stock - Frequently Asked Questions

Should I buy or sell InflaRx stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IFRX shares.
View IFRX analyst ratings
or view top-rated stocks.

What is InflaRx's stock price forecast for 2023?

5 equities research analysts have issued 12-month price targets for InflaRx's shares. Their IFRX share price forecasts range from $8.00 to $25.00. On average, they expect the company's share price to reach $14.00 in the next year. This suggests a possible upside of 237.3% from the stock's current price.
View analysts price targets for IFRX
or view top-rated stocks among Wall Street analysts.

How have IFRX shares performed in 2023?

InflaRx's stock was trading at $3.10 at the beginning of the year. Since then, IFRX stock has increased by 33.9% and is now trading at $4.15.
View the best growth stocks for 2023 here
.

Are investors shorting InflaRx?

InflaRx saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 705,400 shares, a decline of 26.3% from the April 30th total of 956,900 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio is presently 0.3 days.
View InflaRx's Short Interest
.

When is InflaRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IFRX earnings forecast
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03.

What ETF holds InflaRx's stock ?

Invesco Raymond James SB-1 Equity ETF holds 63,995 shares of IFRX stock, representing 0.23% of its portfolio.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

Who are InflaRx's major shareholders?

InflaRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Raymond James Financial Services Advisors Inc. (0.35%), Susquehanna International Group LLP (0.24%), Commonwealth Equity Services LLC (0.20%), JPMorgan Chase & Co. (0.16%) and Raymond James & Associates (0.13%).

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $4.15.

How much money does InflaRx make?

InflaRx (NASDAQ:IFRX) has a market capitalization of $185.51 million. The company earns $-31,070,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The official website for the company is www.inflarx.de. The company can be reached via phone at 493641508180 or via email at jordan.zwick@inflarx.de.

This page (NASDAQ:IFRX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -